Attgeno AB, home of Supernitro, is a Swedish clinical stage pharmaceutical company founded by a research group at the Karolinska Institute, Stockholm, to develop and bring to market new nitric oxide (NO)-donating technology and products. Our first drug candidate, Supernitro, is based on a novel principle developed by Attgeno and is intended to reverse life-threatening high blood pressure in the lungs (acute pulmonary hypertension, aPH).
View Top Employees from Attgeno| Website | https://attgeno.com/ |
| Revenue | $1 million |
| Employees | 10 (4 on RocketReach) |
| Founded | 2006 |
| Address | 2a Fogdevreten, Solna, Stockholm 171 65, SE |
| Phone | +46 70 645 78 27 |
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Drug Discovery, Manufacturing, Biotechnology |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Attgeno employee's phone or email?
Attgeno Questions
The Attgeno annual revenue was $1 million in 2024.
Bjorn Westberg is the CFO of Attgeno.
4 people are employed at Attgeno.
Attgeno is based in Solna, Stockholm.
The NAICS codes for Attgeno are [3254, 325, 32541, 32].
The SIC codes for Attgeno are [28, 283, 2834].
Top Attgeno Employees
-
55+
-
2
-
1
Related Companies
